GS-441524 and remdesivir: where we started and what we have learnt

Overview

Learning Objectives:

  • Summarise the evidence supporting GS-441524 and remdesivir as effective treatments for FIP.
  • Explain current consensus recommendations (ISCAID treatment guideline) regarding first-line antiviral therapy for FIP.
  • Compare GS-441524 and remdesivir with other nucleoside analogues in terms of evidence and clinical outcomes.
  • Describe key lessons learned about dose optimisation and preferred route of administration across different clinical presentations of FIP.

Presenters

Dr Sally Coggins

Dr Sally Coggins

BVSc (Hons I), MANZCVS (Feline Medicine), PhD

Communicating with caregivers about FIP

By the end of this webinar, participants should be able to: Explain key information caregivers need…

Supportive care: treating FIP is more than just antivirals

Supportive care: treating FIP is more than just antivirals Register here Already registered Overview…

Beyond FIP: the role of coronavirus in multi-cat households and catteries

By the end of this lecture, participants will be able to: Describe the epidemiology, transmission…
Load More